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a b s t r a c t
Ethnopharmacological relevance: Syzygium cumini (L.) Skeels (Myrtaceae), commonly known as “jambo-
lão” in Brazil is widely used in folk medicine against leishmaniasis, inﬂammation, chronic diarrhea, and
ulcers. It is one of the most commonly used plants for the treatment of diabetes worldwide. In previous
studies, Syzygium cumini was shown to possess antihyperlipidemic and anti-allergic properties, and to
exhibit good performance as an antimicrobial agent against bacteria, fungi, and protozoa parasites of the
genus Leishmania and Trypanosoma. This study was aimed at evaluating the effects of S. cumini essential
oil (ScEO) and its major component α-pinene on Leishmania (Leishmania) amazonensis, as well as their
cytotoxicity and possible mechanisms of action.
Materials and methods: To evaluate the anti-proliferative effect on Leishmania, effects on promastigote and
axenic amastigote forms were assessed using tetrazolium salt (MTT) assay. The intramacrophagic amastigotes
were exposed to ScEO and α-pinene to determine the survival index. To gain insight into the mechanism of
action involved in the effect on the samples, we evaluated the modulation of macrophage activation state by
observing structural (phagocytic and lysosomal activities) and cellular (nitric oxide increase) changes. To
assess the safety proﬁle of ScEO and α-pinene, murine macrophages and human red blood cells were treated
with ScEO and α-pinene and the selectivity index was calculated for each treatment.
Results: α-Pinene was effective against Leishmania amazonensis promastigote forms, with a half-maximal
inhibitory concentration (IC50) value of 19.7 mg/mL. α-Pinene was more active (IC50 values of 16.1 and 15.6 mg/
mL against axenic and intracellular amastigotes, respectively) than ScEO (IC50 values of 43.9 and 38.1 mg/mL
against axenic and intracellular amastigotes, respectively). Our results showed that the anti-Leishmania effects
were mediated by immunomodulatory activity, as evidenced by the observed increases in both phagocytic and
lysosomal activity, and the elevated NO levels. ScEO and α-pinene exhibited low cytotoxicity against murine
macrophages and human erythrocytes. The 50% cytotoxicity concentration (CC50) values for the macrophages
in the MTT assay were 614.1 and 425.2 mg/mL for ScEO and α-pinene, respectively, while the corresponding
half-maximal hemolytic concentration (HC50) values were 874.3 and 233.3 mg/mL.
Conclusions: Taken together, the results demonstrate that ScEO and its major constituent α-pinene have
signiﬁcant anti-Leishmania activity, modulated by macrophage activation, with acceptable levels of cytotoxicity
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in murine macrophages and human erythrocytes. Further work is warranted, involving more in-depth
mechanistic studies and in vivo investigations.
& 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Leishmaniasis comprises a complex of parasitic diseases caused
by more than 20 protozoa species of the genus Leishmania,
Trypanosomatidae family, that affect approximately 12 million
people in 88 countries throughout the world (Feasey et al., 2010;
Shukla et al., 2011; WHO, 2014). The life cycle of these parasites
includes two distinct forms: a motile extracellular promastigote
form found in the sand ﬂy vector and a nonﬂagellated intracellular
amastigote form which can be found within the mononuclear
phagocytes in the mammalian host (De Almeida et al., 2003;
Chappuis et al., 2007). The clinical manifestations are diverse and
may range from ulcerative skin lesions to the visceral form, which
is the most severe form of leishmaniasis and is associated with
generalized infection and high mortality (David and Craft, 2009;
Abebe et al., 2012).
The chemotherapy currently available for the treatment of
leishmaniasis is far from satisfactory. The ﬁrst choice treatment
was introduced in 1945 and is still based on pentavalent anti-
monials (SbV)—meglumine antimoniate (Glucantimes) and
sodium stibogluconate (Pentostams). The second-line drugs
amphotericin B, pentamidine, and paromomycin are used in cases
of antimonial resistance. However, these drugs have important
limitations, including toxic side effects, high cost, and the need for
prolonged treatment (Croft and Coombs, 2003; Dos Santos et al.,
2011; Monte Neto et al., 2011; Tiuman et al., 2011). Given these
limitations, there is an urgent need for the discovery of new
therapies against leishmaniasis.
Different strategies have been attempted to obtain novel com-
pounds effective against Leishmania spp. A number of natural products
with diverse structural classes showed anti-Leishmania properties,
including monoterpenes, sesquiterpenes, and other constituents of
essential oils, demonstrating that such substances may be promising
research options for the development of new drugs (Ueda-Nakamura
et al., 2006; Angel et al., 2014).
Syzygium cumini (L.) Skeels (Syn. Eugenia jambolana Lam. or
Syzygium jambolana Dc or Eugenia cuminii Druce), commonly known
as “jambolão” in Brazil, is an evergreen tree belonging to the family
Myrtaceae (Faria et al., 2011). It originated in tropical Asia, speciﬁcally
in the Indian subcontinent, and is common in regions with tropical
and subtropical climate, which can be found in most Brazilian states
(Schossler et al., 2004; Baliga et al., 2011). Phytochemical investigations
reported that Syzygium cumini leaves contain various terpenoids,
alkaloids, lignans, and phenolics, including quercetin, myricetin, sitos-
terol, myricetin, and betulinic acid (Mir et al., 2009; Srivastava and
Chandra, 2013). The medicinal uses of Syzygium cumini have been
recognized in various systems of traditional folk medicine, with
Syzygium cumini being one of the world's most commonly used plants
for the treatment of diabetes (Trojan-Rodrigues et al., 2012; Ayyanar et
al., 2013). In addition, this species has been used for treatment of
leishmaniasis (Ayyanar and Subash-Babu, 2012), diseases caused by
bacteria, fungi and viruses (Maciel et al., 2008), inﬂammation
(Muruganandan et al., 2001), chronic diarrhea (Veigas et al., 2007),
and intestinal and genitourinary tract ulcers (Chandrasekaran and
Venkatesalu, 2004). Previous studies have demonstrated that Syzygium
cumini has anti-allergic (Brito et al., 2007), antihyperglycemic (Oliveira
et al., 2005), antihyperlipidemic (Ravi et al., 2005), antioxidant
(Elangovan et al., 2000), antiviral (Sood et al., 2012), antibacterial
(Bag et al., 2012), antifungal, and trypanocidal (Dos Santos et al., 2012)
properties.
Recently, we focused our attention on the chemical composi-
tion of the essential oil from Syzygium cumini (ScEO) and its
potential activity against promastigote forms of Leishmania (Leish-
mania) amazonensis, one of the etiologic agents of American
tegumentary leishmaniasis (ATL) (Dias et al., 2013). The most
abundant compounds in the essential oil were found to be
monoterpenes (87.12%), with α-pinene (31.85%), (Z)-β-ocimene
(28.98%), and (E)-β-ocimene (11.71%) being the major components.
ScEO has shown signiﬁcant anti-Leishmania activity against the
promastigote forms (IC50 values of 60 mg/mL) (Dias et al., 2013). In
the present study, we report for the ﬁrst time the anti-Leishmania
activity of ScEO and its major constituent α-pinene against
amastigote forms of Leishmania amazonensis, a life stage that is
responsible for the clinical manifestation of leishmaniasis, and
propose a possible mechanism of action.
2. Materials and methods
2.1. Chemicals and drugs
Schneider's and RPMI 1640 culture mediums, Griess reagent (1%
sulfanilamide in H3PO4 10% (v/v) in Milli-Q water), antibiotics peni-
cillin and streptomycin, and other cell culture reagents including fetal
bovine serum (FBS), thioglycollate medium, Zymosan, Neutral Red
(NR), and tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)2,;5-diphenyl-
tetrazolium bromide; MTT) were purchased from Sigma Chemical (St.
Louis, MO, USA). The chemotherapy drug meglumine antimoniate
(Glucantimes; 300 mg/mL) was obtained from Aventis Pharma (São
Paulo, SP, Brazil). Panoptic staining kit was obtained from Laborclin, PR,
Brazil. The reagents glacial acetic acid, ethanol, sodium dodecyl sulfate
(SDS), formaldehyde, sodium chloride, calcium acetate, anhydrous
sodium sulfate, and dimethylsulfoxide (DMSO, 99% purity) were
purchased from Merck Chemical Company (São Paulo, SP, Brazil).
2.2. ScEO and major components
Syzygium cumini leaves were collected and the essential oil was
extracted by conventional steam hydrodistillation. Essential oil was
characterized using gas chromatography–mass spectrometry (GC–
MS), as previously described (Dias et al., 2013). A voucher specimen
was deposited (No. 1079/SLS017213) in the Herbarium “Ático Seabra”
in São Luiz, Maranhão State, Brazil. α-Pinene (C10H16, 98% purity) was
purchased from Sigma Chemical (St. Louis, MO, USA). Its structure is
shown in Fig. 1.
Fig. 1. Chemical structure of α-pinene.
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2.3. Leishmania culture conditions
Leishmania (Leishmania) amazonensis (IFLA/BR/67/PH8) were
maintained as amastigotes in several weekly passages in Swiss
mice and in vitro as promastigotes at 26 1C in supplemented
Schneider's medium, pH 7 (10% heat-inactivated fetal bovine
serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin),
as previously described (Carneiro et al., 2012). Extracellular
amastigote-like forms were obtained by in vitro differentiation of
promastigotes of Leishmania amazonensis in the stationary growth
phase by increasing the temperature to 32 1C and decreasing the
pH to 4.6 (Ueda-Nakamura et al., 2006).
2.4. Animals and peritoneal macrophages
Male and female Swiss mice (4–5 weeks old) obtained from
section biotherium of the Medicinal Plants Research Center, Health
Sciences Center, Federal University of Piauí, (NPPM/CCS/UFPI),
Terezina, Brazil, were maintained under controlled temperature
(2471 1C) and light conditions (12-h light/dark cycle). Murine
peritoneal macrophages were collected from mice 5 days after
intraperitoneal inoculation with 1.5 mL of 3% brewer thioglycollate
medium. Animals were treated according to the Guiding Principles
(NIH publication ♯85-23, revised in 1985) for the Care and Use of
Animals and all experimental protocols were approved by the
Research Ethics Committee (CEEAPI-UFPI/PI no. 001 � 2012).
2.5. Activity against promastigotes and axenic amastigotes of
Leishmania amazonensis
Inhibition of parasite growth was assayed using the MTT
colorimetric assay, as previously described (Valadares et al.,
2011). Brieﬂy, promastigotes or axenic amastigotes in the logarith-
mic growth phase were cultured in 96-well cell culture plates at
1106 parasites per well in 100 mL of Schneider's medium with
increasing concentrations of α-pinene (for wells containing pro-
mastigote and amastigote axenic forms) and ScEO (for wells
containing axenic amastigotes). The plates were incubated for
48 h in a biological oxygen demand (B.O.D.) incubator at 26 1C for
promastigotes and 32 1C for axenic amastigotes. Cell viability was
measured by adding MTT (5 mg/mL) and incubating the cells for
4 h prior to the addition of 10% SDS. The absorbances were
measured using an ELISA plate reader (Biosystems model
ELx800, Curitiba, PR, Brazil) at 540 nm. Glucantimes was used
as a positive control.
2.6. Anti-Leishmania activity against intramacrophagic amastigotes
Macrophages were harvested and plated onto culture plates
with 24 wells at a concentration of 1106 cells/mL in supple-
mented RPMI 1640 (10% inactivated FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin), containing sterile round coverslips at
13 mm. Culture plates were incubated at 37 1C and 5% of CO2 for
3 h for cell adhesion. Adhered macrophages were then incubated
with a new medium containing promastigotes (in stationary
phase) at a ratio of 10 promastigotes to 1 macrophage at 5% CO2
and 37 1C for 4 h. The medium was subsequently aspirated to
remove non-internalized parasites and the wells were washed
with 0.01 M phosphate buffered saline (PBS). The infected culture
was incubated with a range of concentrations of ScEO, α-pinene,
and Glucantimes at concentrations observed not to be toxic to
macrophages for 48 h. After this period, the coverslips were
removed and stained with Panoptic staining kit. For each treat-
ment, the number of infected macrophages and the parasite load
were counted using optical microscopy (Carneiro et al., 2012).
2.7. Determination of cytotoxicity
2.7.1. Cytotoxic effect on macrophages and the calculation of
selective index (SI)
Cytotoxicity evaluation was carried out in 96-well plates using
the MTT assay. Approximately 1106 macrophages per well were
incubated in 100 μL of supplemented RPMI 1640 medium at 37 1C
and 5% CO2 for 4 h for cell adhesion. Non-adherent cells were
removed by washing with RPMI 1640 medium. ScEO and α-pinene
were diluted in supplemented RPMI 1640 medium, added at a
range of concentrations, and incubated at 37 1C with 5% CO2 for
two days. Following incubation, cytotoxicity was assessed by
adding MTT (5 mg/mL). The supernatant was discarded and the
formazan crystals were dissolved by addition of 100 μL of DMSO.
Finally, absorbance at 550 nm was measured using an ELISA plate
reader. Selectivity index of each treatment was calculated by
dividing the 50% cytotoxicity concentration (CC50) observed for
peritoneal macrophages of Swiss mice by the half-maximal inhi-
bitory concentration (IC50), measured for different forms of
Leishmania.
2.7.2. Red blood cell lysis assay
The hemolytic activity was evaluated by mixing 80 mL of a 5%
suspension of fresh human red blood cells (Oþ) in PBS with 20 mL
of different concentrations of ScEO or α-pinene and incubating at
37 1C for 1 h. The reaction was slowed by adding 200 mL of PBS and
the suspension was centrifuged (1000g for 10 min). The super-
natant was transferred to a 96-well plate and cell lysis was
quantiﬁed by spectrophotometrical measurement of absorbance
at 540 nm, as previously described (Löfgren et al., 2008). The
maximal lysis and blank control were obtained by replacing the
extract sample with an equal volume of PBS or distilled water,
respectively. The hemolysis percentage was determined using the
following equation:
Hemolysis ð%Þ ¼ Abs: of sampleAbs: of blank control
Abs: of maximal lysisAbs: of blank control 100
2.8. Immunomodulatory activity
2.8.1. Lysosomal activity
The uptake of the cationic dye NR, which is concentrated in the
lysosomal compartments of macrophages, was assessed as pre-
viously described (Bonatto et al., 2004). Peritoneal macrophages
(1106 cells per well) were harvested and plated with samples in
serial dilutions at 37 1C and 5% CO2 for 48 h. Next, cells were
treated with 10 mL 2% NR in PBS and incubated for 30 min. The
wells were subsequently washed twice with PBS and the inter-
nalized NR was solubilized by adding the extraction solution
(glacial acetic acid 1% v/v, ethanol 50% v/v dissolved in twice-
distilled water). After 30 min on a Kline shaker (model AK 0506),
the absorbance at 550 nm was read using the ELISA plate reader.
2.8.2. Phagocytosis assay
Peritoneal macrophages were plated at a concentration of
1106 cells per well and cultured with the samples at 37 1C and
5% CO2. After 48-h incubation, 10 mL of NR-stained zymosan was
added and the cells were incubated at 37 1C for 30 min. Following
incubation, 100 mL of Baker's ﬁxative (formaldehyde 4% v/v,
sodium chloride 2% w/v, calcium acetate 1% w/v in distilled water)
was added to stop the zymosan phagocytosis. After 30 min, the
cells were washed with PBS to remove NR and zymosan non-
phagocytosed by macrophages. NR was solubilized by adding the
extraction solution in the Kline shaker. The absorbance was
subsequently measured at 550 nm using the ELISA plate reader
(Grando et al., 2009).
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2.8.3. Nitric oxide (NO) production
The NO production was estimated by measuring nitrite levels.
Macrophages (1106 per well) were incubated at 37 1C with 5% CO2
for 4 h for cell adhesion. Half of the treatment groups were
stimulated with Leishmania amazonensis at a 10:1 promastigotes
to macrophages ratio for 30 min. The cells were subsequently
incubated alone in RPMI 1640 medium (background control) or
separately stimulated with either the samples or LPS (2 mg/mL) for
24 h. Following incubation, cell culture supernatant was collected
and mixed with an equal volume of Griess reagent. Absorbance was
determined at 550 nm using a microplate reader. Nitrite production
was extrapolated from a standard curve obtained with a range of
concentrations of sodium nitrite (1–150 μM).
2.9. Statistical analysis
The assays were carried out in triplicate and in three indepen-
dent experiments. Differences between groups were analyzed
using one-way ANOVA with Bonferroni post-hoc test using Graph-
Pad Prisms software version 5.0, considering the P value o0.05 as
statistically signiﬁcant. The IC50, CC50, and half-maximal hemolytic
concentration (HC50) values were calculated using probit regres-
sion model (SPSS program, version 13.0) and assuming a con-
ﬁdence level of 95% (Po0.05).
3. Results
3.1. Anti-Leishmania activity assay
α-Pinene showed cytotoxic effect on promastigotes of Leishmania
amazonensis, with cellular death percentages of 93.7%, 83.2%, and
58.4% observed at concentrations of 100, 50, and 25 mg/mL, respec-
tively (Fig. 2A), with IC50 calculated at 19.7 mg/mL (Table 1). The effect
of ScEO on the promastigotes was previously determined (Dias et al.,
2013). The cytotoxic proﬁle of ScEO and its major constituent
α-pinene was evaluated by in vitro testing against axenic amastigote
forms of Leishmania amazonensis. By comparing the degree of
inhibition following 48 h of exposure, α-pinene was observed to be
the most effective tested substance, with 99.08%, 90.8%, and, 78.97%
inhibition observed at concentrations of 100, 50, and 25 mg/mL
(Fig. 2B), respectively, with an IC50 of 16.1 mg/mL (Table 1). At the
same concentrations, ScEO showed 98.78%, 65%, and 32.5% inhibition
(Fig. 2B), with IC50 of 43.9 mg/mL. Low activity of the reference drug
Glucantimes was observed on axenic amastigotes following 48 h
exposure, with IC50 of 624.5 mg/mL.
3.2. Effect of ScEO and α-pinene on macrophage infection
Results of the treatments with ScEO and α-pinene on macro-
phages infected with Leishmania amazonensis are presented in
Fig. 3 and Table 1. The values obtained showed that the treatment
Fig. 2. Anti-Leishmania activity against promastigotes (A) and axenic amastigotes (B). Parasites (1106) were exposed to different concentrations for 48 h and cell viability
was assessed by tetrazolium salt (MTT). ScEO – Syzygium cumini essential oil. *Po0.05 vs. control; **Po0.01 vs. control; ***Po0.001 vs. control.
Table 1
Anti-Leishmania activity, cytotoxic effects against mammalian cells, and selectivity index values calculated for Syzygium cumini essential oil (ScEO), α-pinene, and
Glucantimes.
Compounds Macrophages Red blood cell Promastigotes Axenic amastigotes Intramacrophagic amastigotes
CC50, lg mL1 HC50, lg mL1 IC50, lg mL1 SIm SIrb IC50, lg mL1 SIm SIrb IC50, lg mL1 SIm SIrb
ScEO 614.1 874.3 60a 10.2 14.5 43,9 13.9 19.9 38.1 16.1 22.9
α-Pinene 425.2 233.6 19.7 21.5 11.8 16.1 26.4 14.5 15.6 27.2 14.9
Glucantime 412.9 139.7 1200a 0.3 0.1 624.5 0.6 0.2 167.4 2.4 0.83
SIm (selectivity index)¼CC50/IC50.
SIrb (selectivity index)¼HC50/IC50.
a Data already published (Dias et al., 2013).
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of macrophages with both ScEO and α-pinene diminished the
survival rate of amastigotes, with ScEO concentrations of 50 and
100 mg/mL (Fig. 3A and E), and α-pinene concentrations of 25, 50,
and 100 mg/mL (Fig. 3B and F) showing an effect. α-Pinene proved
to be more effective than ScEO against intramacrophage amasti-
gotes, with IC50 of 15.6 mg/mL, compared to IC50 of 38.1 mg/mL
calculated for ScEO (Table 1). In addition, Glucantimes activity on
the intracellular amastigotes was demonstrated, with IC50 of
167.4 mg/mL, suggesting that it exhibits higher activity against this
stage of the parasite than against the promastigote stage.
3.3. Cytotoxicity determination
The results of the assessments of ScEO and α-pinene cytotoxi-
city in murine macrophages and human erythrocytes are shown in
Fig. 4 and Table 1. ScEO demonstrated minor cytotoxicity against
macrophages and erythrocytes, with CC50 of 614.1 mg/mL and HC50
of 874.3 mg/mL, while α-pinene reduced the viability of both cells
with CC50 of 425.2 mg/mL and HC50 of 233.6 mg/mL (Table 1).
However, the safety of extracts was expressed as SI values, which
are the ratios between the values of CC50 or HC50 and the IC50 of
different models of anti-Leishmania activity. The SI represents the
number of times that the effect of the substance is more selective
for the parasite rather than to the mammalian cells. α-Pinene
proved to be the safest for macrophages, with SI of 21.5, 26.4, and
27.2 for promastigotes, axenic amastigotes, and intramacrophage
amastigotes, respectively, while ScEO treatments were associated
with SI values of 10.2, 13.9, and 16.1 for the same parasite forms
(Table 1). On the other hand, ScEO was found to be safer for human
blood type Oþ erythrocytes, due to its low observed toxicity
against these cells, with SI of 14.5, 19.9, and 22.9 against promas-
tigotes, axenic amastigotes, and intramacrophage amastigotes,
respectively. α-Pinene SI was determined to be 11.8, 14.5, and
14.9 in the same cells (Table 1). Glucantimes showed the highest
toxicity of the tested substances (CC50 412.9 mg/mL and HC50
139.7 mg/mL), being more toxic to erythrocytes than to parasites
(SI under 1) (Table 1).
3.4. Lysosomal activity and phagocytosis test
Activation parameters of macrophages and immunomodula-
tion, such as the increase in lysosomal volume and phagocytosis,
were assessed on the basis of the retention of neutral red and
phagocytosis of stained zymosan by the macrophages. As shown in
Fig. 5A, ScEO promoted a volume increase in the endocytic
compartment at concentrations of 50, 100, and 200 mg/mL, while
Fig. 3. Effect of Syzygium cumini essential oil (ScEO), α-pinene, and the reference drug Glucantimes on the survival index of amastigotes internalized in macrophages after 48 h of
exposure. Murine macrophages were infected with promastigote form of Leishmania amazonensis and treated at different concentrations of ScEO (A), α-pinene (B), and Glucantimes
(C). Detail of non-treated macrophage (D). Detail of macrophage treated with 50 mg/mL of ScEO (E). Detail of macrophage treated with α-pinene at 50 mg/mL (F). Arrows indicate
amastigote forms within the macrophages. Results represent the means7S.E.M. of three experiments performed in triplicate. (*) Po0.05 vs. control; **Po0.01 vs. control;
***Po0.001 vs. control. C¼control.
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α-pinene signiﬁcantly increased the retention of the neutral red in
the secretory vesicles of macrophages at 25, 50, and 200 mg/mL
concentrations (Fig. 5B). Similarly, the phagocytic activity of
macrophages was augmented by a treatment with ScEO at 200
and 400 mg/mL concentrations (Fig. 5C), and by α-pinene at 100,
200, and 400 mg/mL concentrations (Fig. 5D).
3.5. Measurement of nitric oxide (NO) production
The production of nitric oxide (NO), an index of macrophage
activation, was quantiﬁed by measuring the concentrations of nitrites
made by macrophages incubated in the presence or absence of the
promastigote forms of Leishmania amazonensis. Incubation with ScEO
Fig. 4. Cytotoxic effects of Syzygium cumini essential oil (ScEO) and α-pinene against murine macrophages (A) and human erythrocytes (B). Murine macrophages were
incubated for 48 h in the presence of different concentrations. Macrophage viability was measured by tetrazolium salt (MTT) assay. Hemolytic activity was assessed in a 5%
suspension of human erythrocytes after 1 h of incubation. Data are expressed as means7S.E.M. of three experiments performed in triplicate.
Fig. 5. The inﬂuence of Syzygium cumini essential oil (ScEO) and α-pinene on the lysosomal volume (A) and phagocytic activity (B). Murine macrophages were treated with a
range of concentrations for 48 h. Lysosomal activity was analyzed spectrophotometrically by quantifying the increase in neutral red (NR) uptake following solubilization with
the extraction solution. The phagocytosis was analyzed by incorporation of NR-stained zymosan, solubilized with the extraction solution. Data are presented as mean7S.E.
M. of three experiments carried out in triplicate. *Po0.05 vs. control; **Po0.01 vs. control. C¼control.
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increased NO production at concentrations of 50 to 400 mg/mL not
only in Leishmania-stimulated macrophages but also in macrophages
incubated without Leishmania (Fig. 6A). Macrophages treated with
α-pinene demonstrated an increase in the concentration of nitrites
and, consequently, NO at concentrations between 50 and 400 mg/mL
in stimulated macrophages and 100–400 mg/mL in non-stimulated
macrophages (Fig. 6B). Bacterial lipopolysaccharide (LPS) was used as a
positive control, showing high NO production (Fig. 5).
4. Discussion
In the elucidation of new treatments for leishmaniasis, research
evaluating the active compounds present in vegetable species was
found to be very promising. Among these compounds, a number of
essential oils, complex mixtures of volatile substances, have
presented with anti-Leishmania activity against different forms of
the parasite through in vitro and in vivo tests. Studies with
essential oils of Ocimum gratissimum L. (Ueda-Nakamura et al.,
2006), Copaifera cearensis Huber ex Ducke (Santos et al., 2008),
Chenopodium ambrosioides L. (Monzote et al., 2006), Cymbopogon
citratus (D.C.) Stapf (Santin et al., 2009; Machado et al., 2012), and
Lippia sidoides Cham. (Oliveira et al., 2009) demonstrated the
potential of these substances in the search for new anti-Leishmania
agents. We have previously reported that ScEO showed cytotoxic
effects against the promastigote form of Leishmania amazonensis
(Dias et al., 2013). Here, we report the activity of its major
constituent, α-pinene, which was shown to be even more effective
than the essential oil against promastigotes. Many major consti-
tuents extracted from other essential oils present better anti-
Leishmania activity when isolated than when applied in the
mixture. Thymol (De Medeiros et al., 2011) and linalool (Rosa
et al., 2003) are illustrative examples of this difference in efﬁcacy
between formulations. The differences between the pharmacolo-
gical activities of essential oils and their isolated compounds result
from mutually antagonizing effects between the secondary com-
pounds which may inﬂuence the reabsorption rate of reagents and
therefore alter the bioavailability of active compounds (Bakkali
et al., 2008).
Essential oils have some speciﬁcations regarding their mechan-
ism of anti-Leishmania action. Due to the lipophilic character of the
components, they easily pass through cytoplasmic membranes,
interfering with their composition, comprising polysaccharides,
fatty acids, and phospholipids, turning the membranes permeable
and promoting cell lysis. In addition to the effect on the mem-
brane, components of the essential oils interfere with the potential
of the mitochondrial membranes, causing a release of free radicals
that act on the DNA of the parasite, and could thereby lead to
apoptosis or necrosis of the cells (Tariku et al., 2010, 2011). The
drive towards minimizing the use of animals in laboratories, not
only in evaluations of the pharmacologic action but also in studies
evaluating the toxicity of novel compounds, has led towards the
development of alternative in vitro methods that are to be used
whenever possible. Experimental models using amastigotes of
Leishmania are important, since these forms are responsible for
the clinical manifestations of the leishmaniasis (Di Giorgio et al.,
2005). Axenic amastigote cultures have been developed for use in
studies with this stage of the parasite life cycle, facilitating the
screening of novel drugs (De Muylder et al., 2011). Furthermore,
models with the intracellular form provide the most efﬁcient
method for relating the in vitro activity of a drug with its
effectiveness in the in vitro assay (Martinez-Rojano et al., 2008).
Leishmania amastigote form presents higher sensitivity to the
treatment with ScEO, α-pinene, and Glucantimes than the pro-
mastigote form. The difference in the anti-Leishmania activity may
be related to the biochemical and metabolic differences between
the two stages (Gupta et al., 2001). Moreover, the higher activity
against intramacrophage amastigotes observed with ScEO and
α-pinene treatments may indicate the activation of anti-Leishma-
nia activities of the macrophages (Kolodziej and Kiderlen, 2005).
To exert their microbicide activities, macrophages develop both
structural (spreading, phagocytosis, vacuolization, and increased
lysosomal volume) and cellular mechanisms (changes in the NO
proﬁle, altered cytokine levels, and matrix metalloproteinase
secretion) (Bonatto et al., 2004; Bhattacharya et al., 2013). In the
present work, we evaluated two structural mechanisms of anti-
Leishmania activity (lysosomal and phagocytic activities), as well
as the cellular mechanism of induction of the NO synthesis
through the modulation of the state of activation of macrophages.
Our results showed that ScEO and α-pinene increase both para-
meters, suggesting the involvement of these mechanisms in their
anti-Leishmania activity. Phagocytosis and lysosomal activity are
functions of the innate immunity, important for the control of
infections and leading to the degradation of pathogens and
presentation of antigens (Harrison et al., 2003; Niedergang and
Chavrier, 2004). After pathogen endocytosis, the newly formed
Fig. 6. Production of nitric oxide (NO) by non-stimulated and Leishmania-stimulated murine macrophages. Murine macrophages were treated with Syzygium cumini
essential oil (ScEO) (A) and α-pinene (B) for 24 h. After this period, cell-free culture media were mixed with Griess reagent. LPS – bacterial lipopolysaccharide (2 mg/mL). Data
are presented as mean7S.E.M. of three experiments carried out in triplicate. aPo0.05 vs. Leishmania-stimulated control; bPo0.05 vs. Leishmania-unstimulated cells of the
same group; cPo0.05 vs. Leishmania-unstimulated control cells. C¼control.
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phagosome undergoes fusion with endosomes, followed by fusion
with lysosomes to produce a phagolysosome (Niedergang and
Chavrier, 2004). The phagolysosome is a compartment ﬁlled with
acid hydrolases and reactive oxygen species in which most of the
degradation of the encompassed content occurs. Phagocytized
pathogens are thus killed within the phagolysosome (Lee et al.,
2003; Lopes et al., 2006). An important pathway that may be
involved in the mechanism of anti-Leishmania activity could be the
stimulation of NO production in the macrophages. NO was
considered for a very long time to be the most effective mechan-
ism involved in the defense against Leishmania (Gantt et al., 2001).
NO is created following the activation of macrophages by cyto-
kines such as interferon-γ (IFN-γ) and tumor necrosis factor α
(TNF-α). Once inside the phagolysosome, NO combines with the
superoxide anion to produce peroxynitrite, which is highly reac-
tive and acts as a microbicide (Bogdan and Röllinghoff, 1998;
Ueda-Nakamura et al., 2006). Aiming to investigate the safety of
ScEO and α-pinene on the mammalian cells and evaluate the
selectivity of these substances for the parasite, we evaluated the
cytotoxicity of the substances in murine peritoneal macrophages
and human erythrocytes. ScEO and α-pinene displayed a good
safety proﬁle with both cell types, as shown by the SI relative to
the promastigotes, axenic amastigotes, and intramacrophage ama-
stigotes. The high selectivity for the parasite justiﬁes future studies
evaluating the anti-Leishmania activity of ScEO and α-pinene
through in vivo models to gain insight into other mechanisms of
action that may be involved. In contrast to the evaluated plant
extracts, Glucantimes was shown to have SI lower than 1,
indicating higher toxicity to macrophages than to Leishmania. This
result can be explained by the in vivo effects of the pentavalent
antimonials. Even though this drug class is the ﬁrst choice for the
treatment of cutaneous and visceral leishmaniasis, these drugs
cause high toxicity and several side effects (Misra et al., 2010).
5. Conclusions
Based on the results of this study, we can conclude that ScEO
and α-pinene are biologically active against both stages of Leish-
mania amazonensis, while being safe for mammalian cells. This
study also showed that the anti-Leishmania activity is mediated by
immunomodulation, as evidenced by the stimulation of NO
production and the observed increases in both phagocytic and
lysosomal activities. Further work is warranted, involving more in-
depth mechanistic studies and in vivo investigations.
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